BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...
Seeking Alpha

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference ...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics ...
Pharmabiz

BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC

BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...